Table V.
Published results in the current literature concerning surivival and control in RCC/melanoma cerebral metastases.
| Authors | Cases | Local control | Survival | Local recurrence |
|---|---|---|---|---|
| Brown et al(8) | 16 RCC; 23 melanoma −83 lesions |
100% at 6 months | Median OS, 14.2 months | 12% |
| Buchsbaum et al(1) | 74 melanoma | NR | Median, 5.5 months | NR |
| Chang et al(10) | 44 melanoma, 37 renal, 18 breast, 3 colon, 39 non-small cell lung, 5 sarcoma, 5 other | 1 year, 69% response, 2 years, 46% response | NR | NR |
| Chang et al(20) | 103 melanoma, 77 RCC, 9 sarcoma − 264 lesions | 1 year, 64% RCC; 47% melanoma; 0% sarcoma |
Median, 7.5 months; 1 year, 40% RCC; 25% melanoma; 22% sarcoma |
NR |
| Clarke et al(9) | 27 RCC + melanoma | 3 months, 82.8% response 6 months, 77.9% response 9 months, 69.3% response 12 months, 69.3% response 18 months, 55.4% response |
NR | 26% |
| Gieger et al(11) | 12 melanoma, 21 lesions | 57% | NR | 43% |
| Goyal et al(21) | 29 RCC − 66 lesions | NR | Median, 10 months | 9% |
| Halperin and Harisiadis (2) | 35 RCC | 30% | NR | NR |
| Kim et al(27) | 26 lung, 7 kidney, 3 breast, 3 colon − 121 lesions | 1 year, 48% | Median, 46 weeks 1 year, 39% response 6 months, 63% response |
NR |
| Lavine et al(13) | 45 melanoma | 97% | Median, 43 months | NR |
| Lo et al(29) | 38 melanoma + RCC - 66 lesions |
3 months, 87.9% response 6 months, 81.4% response 9 months, 67.9% response 12 months, 67.9% response 18 months, 60.3% response |
Corresponding PFS, 55.3, 41.9, 33, 23.3, 13.3% | NR |
| Maor et al(3) | 46 RCC | NR | Median, 8 | weeks NR |
| Marko et al(23) | 19 RCC | 95% | Mean, 21.5 months; Median, 13.6 months |
NR |
| Mori et al(14) | 60 melanoma − 118 lesions | 90% | Median, 7 months | 11.6% |
| Mori et al(31) | 35 RCC − 52 lesions | 90% | Median, 11 months | 10.2% |
| Payne et al(24) | 21 RCC − 37 lesions | 100% | NR | 0% |
| Powell et al(15) | 50 melanoma, 23 RCC, 3 sarcoma | 1 year, 77.7% response | Median OS, 5.1 months | NR |
| Radbill et al(16) | 51 melanoma − 188 lesions | 81% | Median OS, 26 weeks | NR |
| Schoggl et al(25) | 23 RCC − 44 lesions | 96% | Median, 11 months; 1 year, 48% |
NR |
| Selek et al(17) | 103 melanoma − 153 lesions | 1 year, 49% response | 1 year OS, 25.2% | NR |
| Seung et al(18) | 55 Melanoma | 6 months, 89% response 1 year, 77% response |
Median, 35 weeks | NR |
| Sheehan et al(32) | 69 RCC − 146 lesions | 96% | Median, 15 months | 4% |
| Shuto et al(26) | 69 RCC | 82.6% | Median OS, 9.5 months | NR |
| Wronski et al(4) | 119 RCC | NR | 6 months, 33.6% response 1 year, 16.8% response 2 years, 5.9% response Median, 3.4 months |
NR |
| Yu et al(19) | 122 melanoma − 332 lesions | NR | Median, 7 months | NR |
| Kano et al(22) | 158 RCC − 531 lesions | 92% | OS at 6 months, 60% 12 months, 38% 24 months, 19% Median, 8.2 months |
NR |
NR, Not reported; RCC, renal cell carcinoma.